Contineum CEO sells 10,000 shares near $16
Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 10,000 shares of Class A Common Stock and on the same day sold 10,000 shares in an open-market transaction.
Rhea-AI Filing Summary
Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 10,000 shares of Class A Common Stock and on the same day sold 10,000 shares in an open-market transaction. The sale used a weighted average price of $16.008 per share, with individual trades between $16.00 and $16.12.
The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. After the transactions, Stengone directly holds 17,217 Class A shares, including 5,605 acquired through the company’s Employee Stock Purchase Plan, and retains stock options covering 118,417 shares at $1.26 and 281,930 shares at $1.01 exercise prices.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 7,500 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 2,500 | $0.00 | $0.00 |
| Exercise | Class A Common Stock | 7,500 | $1.01 | $8K |
| Exercise | Class A Common Stock | 2,500 | $1.26 | $3K |
| Sale | Class A Common Stock | 10,000 | $16.008 | $160K |
Footnotes (4)
- F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.12, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3. Includes 5,605 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
- F4. Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
Employee Stock Purchase Plan financial
weighted average price financial
Equity Incentive Plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.